117 related articles for article (PubMed ID: 23692186)
21. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
[TBL] [Abstract][Full Text] [Related]
22. Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor.
Washington MC; Raboin SJ; Thompson W; Larsen CJ; Sayegh AI
Brain Res; 2010 Jul; 1344():124-33. PubMed ID: 20452329
[TBL] [Abstract][Full Text] [Related]
23. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity.
Gong N; Xiao Q; Zhu B; Zhang CY; Wang YC; Fan H; Ma AN; Wang YX
J Neurosci; 2014 Apr; 34(15):5322-34. PubMed ID: 24719110
[TBL] [Abstract][Full Text] [Related]
24. Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
Lebovitz HE; Banerji MA
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S43-50. PubMed ID: 22650224
[TBL] [Abstract][Full Text] [Related]
25. Acute effects of glucagon-like peptide-1, GLP-1
Bremholm L; Andersen UB; Hornum M; Hilsted L; Veedfald S; Hartmann B; Holst JJ
Physiol Rep; 2017 Feb; 5(4):. PubMed ID: 28235974
[TBL] [Abstract][Full Text] [Related]
26. [Exenatide stimulated solute-free water excretion by human kidney].
Shakhmatova EI; Shutskaia ZhV; Vladimirova ME; Gorelov AI; Gorbunov AI; Natochin IuV
Ross Fiziol Zh Im I M Sechenova; 2012 Aug; 98(8):1021-9. PubMed ID: 23155627
[TBL] [Abstract][Full Text] [Related]
27. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B
Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
[TBL] [Abstract][Full Text] [Related]
28. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
29. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
Leinung MC; Grasso P
Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
[TBL] [Abstract][Full Text] [Related]
30. Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats.
Xuan J; Lin Y; Huang J; Yuan F; Li X; Lu Y; Zhang H; Liu J; Sun Z; Zou H; Chen Y; Gao J; Zhong Y
Peptides; 2013 Aug; 46():172-9. PubMed ID: 23770254
[TBL] [Abstract][Full Text] [Related]
31. Exenatide improves hypertension in a rat model of the metabolic syndrome.
Laugero KD; Stonehouse AH; Guss S; Landry J; Vu C; Parkes DG
Metab Syndr Relat Disord; 2009 Aug; 7(4):327-34. PubMed ID: 19320558
[TBL] [Abstract][Full Text] [Related]
32. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
Ozyazgan S; Kutluata N; Afşar S; Ozdaş SB; Akkan AG
Pharmacology; 2005 Jun; 74(3):119-26. PubMed ID: 15746570
[TBL] [Abstract][Full Text] [Related]
33. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
34. [Similarity of natriuretic action and qualitative differences of the hydrouretic action of 1-deamino-arginine-vasotocin and furosemide in rats].
Kutina AV; Natochin IuV
Eksp Klin Farmakol; 2010 May; 73(5):19-22. PubMed ID: 20597365
[TBL] [Abstract][Full Text] [Related]
35. [Diet and water-salt balance in rats].
Marina AS; Kutina AV; Natochin IuV
Ross Fiziol Zh Im I M Sechenova; 2012 Mar; 98(3):363-72. PubMed ID: 22645945
[TBL] [Abstract][Full Text] [Related]
36. The Cascade System of Osmotic Homeostasis Regulation.
Natochin YV; Marina AS; Shakhmatova EI
Dokl Biol Sci; 2020 Jan; 490(1):5-8. PubMed ID: 32342317
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
38. The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
Roy D; Chadwick KD; Tatarkiewicz K; LaCerte C; Bergholm AM; Brodie T; Mangipudy RS; Parkes D; Graziano MJ; Reilly TP
Diabetes Obes Metab; 2014 Oct; 16(10):910-21. PubMed ID: 24666399
[TBL] [Abstract][Full Text] [Related]
39. [The effect of exenatide analogs on hydruretic function of rat kidney under water load].
Bogolepova AE; Shakhmatova EI
Eksp Klin Farmakol; 2012; 75(11):10-2. PubMed ID: 23323326
[TBL] [Abstract][Full Text] [Related]
40. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
